{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:17:00Z","timestamp":1782947820969,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002135","name":"Hirshberg Foundation for Pancreatic Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-42259-8","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:14:01Z","timestamp":1775308441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Akash R","family":"Boda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan N.","family":"Bandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhna","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venugopalareddy","family":"Mekala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Wall","family":"Fowlkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roszik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Karlyle","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"issue":"10242","key":"42259_CR1","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi, J. D. et al. Pancreatic cancer. Lancet 395 (10242), 2008\u20132020 (2020).","journal-title":"Lancet"},{"issue":"11","key":"42259_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74 (11), 2913\u20132921 (2014).","journal-title":"Cancer Res."},{"key":"42259_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu, D. et al. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: Current limitations and future options. Front. Immunol. 9, 1878 (2018).","journal-title":"Front. Immunol."},{"key":"42259_CR4","doi-asserted-by":"publisher","first-page":"102016","DOI":"10.1016\/j.ctrv.2020.102016","volume":"86","author":"D Schizas","year":"2020","unstructured":"Schizas, D. et al. Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treat. Rev. 86, 102016 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"42259_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide, R. H. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","journal-title":"Annu. Rev. Med."},{"issue":"6024","key":"42259_CR6","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331 (6024), 1612\u20131616 (2011).","journal-title":"Science"},{"issue":"5","key":"42259_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3892\/ol.2020.12037","volume":"20","author":"DK Li","year":"2020","unstructured":"Li, D. K. & Wang, W. Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies. Oncol. Lett. 20 (5), 176 (2020).","journal-title":"Oncol. Lett."},{"issue":"6","key":"42259_CR8","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padron","year":"2022","unstructured":"Padron, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28 (6), 1167\u20131177 (2022).","journal-title":"Nat. Med."},{"issue":"1","key":"42259_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","volume":"30","author":"SA Weiss","year":"2024","unstructured":"Weiss, S. A. et al. A phase II Trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Clin. Cancer Res. 30(1), 74\u201381 (2024).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"42259_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","volume":"21","author":"P Johnson","year":"2015","unstructured":"Johnson, P. et al. Clinical and biological effects of an agonist anti-CD40 antibody: a cancer research UK phase I study. Clin. Cancer Res. 21(6), 1321\u20131328 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"42259_CR11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","volume":"25","author":"RH Vonderheide","year":"2007","unstructured":"Vonderheide, R. H. et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25 (7), 876\u2013883 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"42259_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1158\/2326-6066.CIR-14-0182","volume":"3","author":"J Medina-Echeverz","year":"2015","unstructured":"Medina-Echeverz, J. et al. Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage. Cancer Immunol. Res. 3(5), 557\u2013566 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"42259_CR13","doi-asserted-by":"publisher","first-page":"100464","DOI":"10.1016\/j.xcrm.2021.100464","volume":"2","author":"SJ Blake","year":"2021","unstructured":"Blake, S. J. et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell. Rep. Med. 2 (12), 100464 (2021).","journal-title":"Cell. Rep. Med."},{"issue":"11","key":"42259_CR14","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1002\/ijc.23173","volume":"121","author":"SP Hussain","year":"2007","unstructured":"Hussain, S. P. & Harris, C. C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer. 121 (11), 2373\u20132380 (2007).","journal-title":"Int. J. Cancer"},{"issue":"2","key":"42259_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1378\/chest.118.2.503","volume":"118","author":"CA Dinarello","year":"2000","unstructured":"Dinarello, C. A. Proinflammatory cytokines. Chest 118 (2), 503\u2013508 (2000).","journal-title":"Chest"},{"issue":"5","key":"42259_CR16","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1073\/pnas.0437939100","volume":"100","author":"E Voronov","year":"2003","unstructured":"Voronov, E. et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 100(5), 2645\u20132650 (2003).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"42259_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1479-5876-4-48","volume":"4","author":"AM Lewis","year":"2006","unstructured":"Lewis, A. M. et al. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl Med. 4, 48 (2006).","journal-title":"J. Transl Med."},{"issue":"3","key":"42259_CR18","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.4049\/jimmunol.1001328","volume":"186","author":"PY Lee","year":"2011","unstructured":"Lee, P. Y. et al. IL-1alpha modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil. J. Immunol. 186 (3), 1747\u20131754 (2011).","journal-title":"J. Immunol."},{"issue":"2","key":"42259_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1189\/jlb.0208085","volume":"84","author":"C Brinster","year":"2008","unstructured":"Brinster, C. & Shevach, E. M. Costimulatory effects of IL-1 on the expansion\/differentiation of CD4\u2009+\u2009CD25+Foxp3\u2009+\u2009and CD4\u2009+\u2009CD25+Foxp3- T cells. J. Leukoc. Biol. 84 (2), 480\u2013487 (2008).","journal-title":"J. Leukoc. Biol."},{"issue":"38","key":"42259_CR20","doi-asserted-by":"publisher","first-page":"25900","DOI":"10.1074\/jbc.M707692200","volume":"283","author":"CM Cahill","year":"2008","unstructured":"Cahill, C. M. & Rogers, J. T. Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT\/IkappaB kinase alpha pathway targeting activator protein-1. J. Biol. Chem. 283 (38), 25900\u201325912 (2008).","journal-title":"J. Biol. Chem."},{"issue":"4","key":"42259_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1006\/cyto.2002.1034","volume":"18","author":"YD Jung","year":"2002","unstructured":"Jung, Y. D. et al. Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells. Cytokine 18 (4), 206\u2013213 (2002).","journal-title":"Cytokine"},{"issue":"16","key":"42259_CR22","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1074\/jbc.271.16.9503","volume":"271","author":"D Zhang","year":"1996","unstructured":"Zhang, D. et al. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 271 (16), 9503\u20139509 (1996).","journal-title":"J. Biol. Chem."},{"issue":"7","key":"42259_CR23","doi-asserted-by":"publisher","first-page":"e1120","DOI":"10.1634\/theoncologist.2020-0194","volume":"25","author":"A Amlani","year":"2020","unstructured":"Amlani, A. et al. Successful treatment of cytokine release syndrome with IL-6 blockade in a patient transitioning from immune-checkpoint to MEK\/BRAF inhibition: A case report and review of literature. Oncologist 25(7), e1120\u2013e1123 (2020).","journal-title":"Oncologist"},{"issue":"1","key":"42259_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12885-019-6138-7","volume":"19","author":"K Yoshino","year":"2019","unstructured":"Yoshino, K. et al. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports. BMC Cancer 19(1), 1019 (2019).","journal-title":"BMC Cancer"},{"issue":"5","key":"42259_CR25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 26 (5), 688\u2013692 (2020).","journal-title":"Nat. Med."},{"key":"42259_CR26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190354","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20190354 (2020).","journal-title":"J. Exp. Med."},{"key":"42259_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","volume":"3","author":"AA Tarhini","year":"2015","unstructured":"Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother Cancer. 3, 39 (2015).","journal-title":"J. Immunother Cancer"},{"issue":"8","key":"42259_CR28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.4049\/jimmunol.2000523","volume":"206","author":"S Singh","year":"2021","unstructured":"Singh, S. et al. IL-1alpha mediates innate and acquired resistance to immunotherapy in melanoma. J. Immunol. 206(8), 1966\u20131975 (2021).","journal-title":"J. Immunol."},{"issue":"9","key":"42259_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer. 20 (9), 485\u2013503 (2020).","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"42259_CR30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/eji.201445093","volume":"45","author":"T Kapanadze","year":"2015","unstructured":"Kapanadze, T. et al. Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. Eur. J. Immunol. 45 (4), 1148\u20131158 (2015).","journal-title":"Eur. J. Immunol."},{"key":"42259_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003246","author":"CR Ager","year":"2021","unstructured":"Ager, C. R. et al. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003246 (2021).","journal-title":"J. Immunother. Cancer"},{"issue":"D1","key":"42259_CR32","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M. et al. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53 (D1), D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"42259_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13578-023-01090-8","volume":"13","author":"YC Fan","year":"2023","unstructured":"Fan, Y. C. et al. Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer. Cell. Biosci. 13 (1), 147 (2023).","journal-title":"Cell. Biosci."},{"issue":"5","key":"42259_CR34","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das, S. et al. Tumor cell-derived IL1beta promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 80(5), 1088\u20131101 (2020).","journal-title":"Cancer Res."},{"issue":"2","key":"42259_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/gutjnl-2019-319912","volume":"70","author":"R Takahashi","year":"2021","unstructured":"Takahashi, R. et al. Interleukin-1beta-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Gut 70 (2), 330\u2013341 (2021).","journal-title":"Gut"},{"issue":"2","key":"42259_CR36","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","volume":"27","author":"DH Aggen","year":"2021","unstructured":"Aggen, D. H. et al. Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: Multidimensional analyses. Clin. Cancer Res. 27(2), 608\u2013621 (2021).","journal-title":"Clin. Cancer Res."},{"key":"42259_CR37","doi-asserted-by":"publisher","first-page":"100789","DOI":"10.1016\/j.neo.2022.100789","volume":"28","author":"KM Herremans","year":"2022","unstructured":"Herremans, K. M. et al. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Neoplasia 28, 100789 (2022).","journal-title":"Neoplasia"},{"issue":"1","key":"42259_CR38","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41467-017-01572-7","volume":"8","author":"M Singh","year":"2017","unstructured":"Singh, M. et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat. Commun. 8 (1), 1447 (2017).","journal-title":"Nat. Commun."},{"issue":"11","key":"42259_CR39","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-21-0083","volume":"20","author":"AR Dosch","year":"2021","unstructured":"Dosch, A. R. et al. Targeting tumor-stromal IL6\/STAT3 signaling through IL1 receptor inhibition in pancreatic cancer. Mol. Cancer Ther. 20(11), 2280\u20132290 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"42259_CR40","doi-asserted-by":"publisher","first-page":"p2014","DOI":"10.3389\/fimmu.2019.02014","volume":"10","author":"L Barbier","year":"2019","unstructured":"Barbier, L. et al. Interleukin-1 family cytokines: Keystones in liver inflammatory diseases. Front. Immunol. 10, p2014 (2019).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42259-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:24:10Z","timestamp":1782944650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42259-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42259"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42259-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MAC received grants from ImmunoMet, Inc. and personal fees from ImmunoGenesis, Inc., Alligator Bioscience, Inc., ImmunoOS, Inc., ImmunoMet, Inc., Oncoresponse, Inc., Pieris, Inc., Nurix, Inc., Apetevo, Inc., Servier, Inc., Kineta, Inc., Salarius, Inc., Xencor, Inc., Agenus, Inc., and Mereo. In addition, MAC also has a patent Methods and Composition for Localized Secretion of Anti-CTLA-4 Antibodies that has been issued and licensed to multiple licensees, and a patent Dual specifically antibodies which bind both PD-L1 and PD-L2 and prevent their binding to PD-1 that is pending and licensed with ImmunoGenesis, Inc. SK has ownership interest in Lutris, Iylon, Frontier Medicines, Xilis, Navire and is a consultant for Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, AstraZeneca\/MedImmune, Bayer Health, Redx Pharma, Ipsen, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, Abbvie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson\/Janssen, Genomic Health, Frontier Medicines, Replimune, TaihoPharmaceutical, Cardiff Oncology, Ono Pharmaceutical, Bristol-Myers Squibb-Medarex, Amgen, Tempus, Foundation Medicine, Harbinger Oncology, Inc, Takeda, CureTeq, Zentalis, Black Stone Therapeutics, NeoGenomics Laboratories, Accademia Nazionale Di Medicina, Tachyon Therapeutics and receive research funding from Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech\/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo. VKM reports research support to BioNTech, Pfizer, Bristol Myers Squibb, Genentech, RedX Pharma, and Apollo Therapeutics institutions and consulting for Regeneron, Bristol Myers Squibb, and Novartis outside the submitted work. MS, AB, INB, SC, SA, AA, VM, NWF, and JR declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20160"}}